A 16-Year old with Lemierre’s Syndrome and Multiple Septic Pulmonary
Emboli
Christopher M Oermann, MD
Department of Pediatrics, Children’s Mercy Kansas City, Kansas City MO
Corresponding Author:
Christopher M Oermann, MD
Children’s Mercy Kansas City
2401 Gillham Road
Kansas City, MO 64108
816-302-3354 (telephone)
816-302-9736 (fax)
cmoermann@cmh.edu
Running Head: Pulmonary Septic Emboli in Lemierre Sn
Key Words: Lemierre Syndrome, Septic Emboli
Word Count: 1035
To the Editor,
Lemierre’s syndrome (LS) is a rare disease resulting from infective
thrombophlebitis of the internal jugular vein (JV) following
oropharyngeal infection. The incidence of LS has increased after decades
of decline. Septic pulmonary emboli (PE) are common, but all organ
systems can be involved. Although LS is most often caused byFusobacterium necrophorum , other pathogens have been implicated.
Persistent high fever and organ-specific signs and symptoms result from
the septic emboli (SE). The diagnosis is often suspected following
growth of Fusobacterium from blood cultures and is confirmed by
head/neck imaging. Therapy includes antimicrobials, drainage of
abscesses, and anticoagulation. Significant morbidity/mortality occur if
diagnosis and treatment are delayed. Pediatric pulmonologists must be
familiar with the diagnosis and management of LS.
A previously healthy 16-year old male was admitted to hospital following
two weeks of fever, myalgia, nausea/vomiting/diarrhea with 10-pound
weight loss, and dry cough. He had been evaluated by his primary care
provider (PCP) ten days prior to admission for pharyngitis and fever of
40oC. Rapid streptococcal antigen and SARS-CoV-2
testing were negative, and he was treated with antipyretics. Continued
symptoms led to PCP reevaluation after 7 days. Chest imaging
demonstrated a single round pneumonia in the right lower lobe, and he
received 3 days of azithromycin. He failed to improve and was referred
to the emergency department 3 days later. Computed tomography (CT) of
the chest/abdomen/pelvis demonstrated bilateral pulmonary nodules. He
was admitted for evaluation and treatment.
Considerations from the admitting team included atypical infection
(fungal or mycobacterial) versus e-cigarette or vaping product use
associated lung injury (EVALI), so Pulmonary Medicine service was
consulted. EVALI was thought unlikely based on the radiographic
appearance of the lesions (Figure 1). Additional considerations included
septic PE, paragonimiasis, autoimmune disease with small vessel
vasculitis (polyangiitis with granulomatosis), and inflammatory bowel
disease. Evaluation for these potential diagnoses was initiated and
empiric therapy with vancomycin and ceftriaxone was commenced.
Echocardiogram, infectious diseases testing, and autoimmune evaluation
were all normal. Painful swelling in the right, anterior neck and a
tender spot on his upper right back developed the day after admission.
His blood culture grew gram-negative anaerobic rods, raising concern for
LS. Doppler ultrasound of the neck demonstrated occlusive thrombus
within the right external JV with extension into the internal JV.
Metronidazole was added to his intravenous antimicrobial regimen and
anticoagulation therapy was initiated.
CT Imaging demonstrated normal CNS with confirmation of thrombosis of
the JVs and inflammation over the surrounding soft tissues of the
anterior right neck and a large abscess involving the posterior spinal
musculature of the upper thorax. A drain was placed, and 25 cc of pus
removed. Magnetic resonance imaging of the spine demonstrated extension
of the abscess into the T1 spinous process suggesting osteomyelitis. The
blood culture grew Fusobacterium necrophorum and antibiotic
coverage was changed to ampicillin/sulbactam to treat potential
polymicrobial infection. Fevers resolved, pain and other symptoms
improved, and the drain was removed after 3 days. He was discharged to
continue 6 weeks of ampicillin/sulbactam and anticoagulation therapy.
LS is a rare complication of infections of the head/neck, with a
reported incidence of one per million people per
year.1 Common during the “pre-antibiotic era”, LS
had decreased in incidence for decades but has increased since the
1990s. This is possibly due to better antimicrobial stewardship and
decreased use of antimicrobials for pharyngitis.1Disease is attributed to infections of the tonsils and peritonsillar
tissue in 87% of cases and infections of the pharynx, parotid glands,
sinuses, mastoids, middle ears, and teeth/gums in
13%.2 Males and females are equally
affected.3 LS has been reported in individuals aged 2
months to 78 years, although it is most commonly reported among
previously healthy adolescents and young adults.2,3
LS originates with primary infection of the
head/neck.4 This is followed by spread of the
infection through the soft tissues of the neck resulting in
thrombophlebitis of the internal JV. Dissemination of infection via SE
occurs, with lung involvement in up to 80% and bones/joints in up to
27%.1-4 Additional sites of infection include
cardiovascular, skin/muscles, central nervous system, abdominal organs
(liver and spleen), and kidneys. Pulmonary involvement has included
septic PE, abscess formation, necrotizing pneumonia, empyema,
pneumothorax, pulmonary embolism, and acute respiratory distress
syndrome. LS is most often caused by Fusobacterium necrophorum ,
part of the normal flora of the pharynx, accounting for up to 85%.
Additional causes include other Fusobacterium species, anaerobes
(Bacteroides , Peptococcus , and Peptostreptococcusspecies), and aerobes (Streptococcus , and Staphylococcusspecies), among others. Polymicrobial infections are reported in up to
30%.2 Significant morbidity results from delayed
diagnosis. Mortality has been reported as 4-18%; more recent reviews
suggest a lower rate.3,5
LS often presents 4-12 days after the initiating oropharyngeal
infection, which may have resolved by presentation. Symptoms include
high fever (up to 80%), gastrointestinal (50%), pharyngitis with
cervical adenopathy or neck pain/swelling, myalgia/arthralgia, rigors,
and respiratory symptoms (cough or dyspnea).1,2,5Additional symptoms may be secondary to organ dysfunction caused by SE.
Diagnosis is often made via Doppler ultrasound or CT imaging of the
head/neck or the growth of Fusobacterium from blood/abscess
cultures.
Therapy for LS involves long term, intravenous antibiotics, surgical
drainage of abscesses, and anticoagulation.1-5Metronidazole is often reported as standard therapy for LS. Other
antibiotic considerations include carbapenems or
penicillin/beta-lactamase inhibitor combinations, which provide broader
coverage for polymicrobial infections. Duration of therapy is 4-6 weeks,
allowing for adequate penetration of thrombi and treatment of secondary
problems such as osteomyelitis. Anticoagulation therapy is more
controversial; some data suggest that anticoagulation hastens overall
response while others indicate adequate clinical response without
additional therapy.
LS is a rare disorder of the head/neck that may be associated with
significant morbidity/mortality if diagnosis and treatment are delayed.
Pediatric pulmonologists will typically encounter LS in patients
hospitalized with prolonged fever and multiple septic PE. LS must be
considered in every child with multiple cavitary nodules identified on
chest imaging. This is particularly true if there is a history of
preceding oropharyngeal infection or signs/symptoms suggesting pathology
in the head/neck. The growth of Fusobacterium species from blood
culture or abscesses should also suggest LS. Doppler ultrasound
examination of the neck and CT imaging of the head/neck should be
obtained. Therapy is long-term, intravenous antibiotics. Adjuvant
therapy includes surgical incision and drainage of abscesses and
anticoagulation therapy.